Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go

被引：47
|
作者：
Lv, Meng [1 ]
Huang, Xiao-Jun [1 ]
机构：
[1] Peking Univ, Inst Hematol, Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2012年 / 5卷
基金：
中国国家自然科学基金;
关键词：
China; Allo-HSCT; Haploidentical; Relapse; GVHD; Elderly patients; ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; DONOR LYMPHOCYTE INFUSION; RISK ACUTE-LEUKEMIA; ACUTE GVHD; ANTITHYMOCYTE GLOBULIN; MYCOPHENOLATE-MOFETIL; CLINICAL-OUTCOMES; T-CELLS; BLOOD;
D O I：
10.1186/1756-8722-5-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative therapy for patients with certain hematological diseases. Allo-HSCT has been practiced in China for approximately 30 years, and great improvements have been made within the past decade, particularly in fields such as the haploidentical HSCT system, strategies to overcome relapse and GVHD, and modified HSCT for elderly patients. This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China.
引用
收藏
页数：8
相关论文
共 50 条
  • [21] South African transplantation - where are we now and where should we go next?
    Muller, Elmi
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2011, 101 (01): : 9 - 9
  • [22] Melanoma: Where we are and where we go
    Mohammadpour, Ali
    Derakhshan, Maryam
    Darabi, Hassan
    Hedayat, Pegah
    Momeni, Mohammad
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (04) : 3307 - 3320
  • [23] Uterus transplantation:: where do we stand today and where should we go?
    Brannstrom, Mats
    Wranning, Caiza Almen
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (04) : 427 - 429
  • [24] Clinical perspectives of cell death: where we are and where to go…
    Boris Zhivotovsky
    Sten Orrenius
    Apoptosis, 2009, 14 : 333 - 335
  • [25] Immunoteratology: Where we are and where to go
    Toder, V
    Torchinsky, A
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1996, 35 (02): : 114 - 117
  • [26] Where we were, where we are now, and where we hope to go
    Main, Joyce B.
    Knight, David B.
    JOURNAL OF ENGINEERING EDUCATION, 2023, 112 (02) : 249 - 250
  • [27] Hematopoietic cell transplantation and HIV cure: where we are and what next?
    Zou, Shimian
    Glynn, Simone
    Kuritzkes, Daniel
    Shah, Monica
    Cook, Nakela
    Berliner, Nancy
    BLOOD, 2013, 122 (18) : 3111 - 3115
  • [28] The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: Where do we stand?
    Serdar Sivgin
    Bulent Eser
    Annals of Hematology, 2013, 92 : 577 - 586
  • [29] The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: Where do we stand?
    Sivgin, Serdar
    Eser, Bulent
    ANNALS OF HEMATOLOGY, 2013, 92 (05) : 577 - 586
  • [30] CardioMEMS: where we are and where can we go?
    Pour-Ghaz, Issa
    Hana, David
    Raja, Joel
    Ibebuogu, Uzoma N.
    Khouzam, Raini
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (17)
12345